Pulmonary Medicine

Host: Ana C. Krieger, MD

This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.

This program covers best practices in:

• Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
• Exploring the relationship between cardiovascular disease and Narcolepsy
• Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle

Host: Matthew Davis, MD

Host: Alcibiades J. Rodriguez, MD, FAASM

The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.

Host: Jacob Sands, MD

Guest: Liza Villaruz, MD

According to a recent study, the immune checkpoint inhibitor durvalumab is not only considered safe, but it may also offer overall survival benefits for individuals with advanced or metastatic non-small cell lung cancer (NSCLC) and restricted performance status. Here to talk about this research are Dr. Jacob Sands and Dr. Liza Villaruz, Associate Professor of Medicine at the University of Pittsburgh School of Medicine.

Host: Charles Turck, PharmD, BCPS, BCCCP

Guest: Justin Reinert, PharmD

Acute respiratory distress syndrome (ARDS) is a severe lung condition characterized by the rapid onset of widespread inflammation in the lungs, but inhaled epoprostenol can be used as a last-line treatment strategy for these patients. Learn more about this treatment option’s efficacy and safety with Dr. Charles Turck and Dr. Justin Reinert, Assistant Professor of Clinical Pharmacy at the University of Toledo.

Host: Andrew Wilner, MD, FACP, FAAN

Guest: Neil Skolnik, MD

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recently updated some of the recommendations for treating patients with chronic obstructive pulmonary disease (COPD). Two large conceptual changes occurred in this update: one is an increased emphasis on treating exacerbations, and the other is looking at decreasing mortality as an important treatment goal. Learn more about this and other key updates from the GOLD recommendations with Dr. Andrew Wilner and Dr. Neil Skolnik, Professor of Family and Community Medicine at the Sidney Kimmel Medical College of Thomas Jefferson University in Philadelphia.

Host: Jennifer Shu, MD, FAAP

Guest: Steven H. Abman, MD

Bronchopulmonary dysplasia is a chronic lung disease that can have significant impacts on a newborn’s overall respiratory health, making it imperative to know how to recognize and treat it. Tune in to hear Dr. Jennifer Shu talk about the symptoms, impacts, and treatment of bronchopulmonary dysplasia with Dr. Steven Abman, a Professor in the Department of Pediatrics at the University of Colorado School of Medicine and the Director of the Pediatric Heart Lung Center at Children’s Hospital Colorado.

Guest: Julie A. Barta, MD, ATSF

Host: Peter J. Mazzone, MD, MPH, FCCP

Lung cancer is most treatable when detected at early stages, yet fewer than 5% of eligible adults are screened using the recommended low-dose CT scan. Blood-based tests for early detection of lung cancer are in development. Join Dr. Peter Mazzone and Dr. Julie Barta as they discuss the latest data on these tests with potential to improve screening rates and outcomes in high-risk individuals.

Host: Jacob Sands, MD

Guest: Aliyah Pabani, MD

Lung cancer patients undergoing immunotherapy may be at risk for developing life-threatening toxicities. Find out how you can manage them with Dr. Jacob Sands and Dr. Aliyah Pabani, Clinical Assistant Professor in the Department of Medicine at the University of Calgary and Director of the Alberta Immunotherapy Database.

Guest: Ashwin Basavaraj, MD

Host: Christopher Lippincott, MD, MPH

From airway clearance techniques and mucoactive therapy—what can clinicians do to manage bronchiectasis exacerbations? To answer this question, Dr. Christopher Lippincott and Dr. Ashwin Basavaraj explore the mechanisms that lead to bronchiectasis and share strategies to manage exacerbations.

This program is produced in partnership with the American College of CHEST Physicians, and is sponsored by Insmed Incorporated.

Host: Ashwin Basavaraj, MD

Guest: Christopher Lippincott, MD, MPH

Bronchiectasis is a complex syndrome that can lead to an interconnected cascade of airway dysfunction and inflammation. How has our understanding of this syndrome evolved with Cole’s vicious cycle hypothesis? Dr. Ashwin Basavaraj and Dr. Christopher Lippincott take a closer look at this hypothesis and the clinical mechanisms behind bronchiectasis.

This program is produced in partnership with the American College of CHEST Physicians, and is sponsored by Insmed Incorporated.